{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:19:38Z","timestamp":1772713178630,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00277-025-06389-9","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T12:34:30Z","timestamp":1747744470000},"page":"2745-2753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in newly diagnosed and relapsed\/refractory acute myeloid leukemia: results of a single center study"],"prefix":"10.1007","volume":"104","author":[{"given":"Ting","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anyou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"6389_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373:1136\u20131152. https:\/\/doi.org\/10.1056\/NEJMra1406184","journal-title":"N Engl J Med"},{"key":"6389_CR2","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3390\/cancers11020224","volume":"11","author":"F Ferrara","year":"2019","unstructured":"Ferrara F, Lessi F, Vitagliano O et al (2019) Current therapeutic results and treatment options for older patients with relapsed acute myeloid leukemia. Cancers (Basel) 11:224. https:\/\/doi.org\/10.3390\/cancers11020224","journal-title":"Cancers (Basel)"},{"key":"6389_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.bbmt.2015.10.019","volume":"22","author":"A Rashidi","year":"2016","unstructured":"Rashidi A, Ebadi M, Colditz GA, DiPersio JF (2016) Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: A systematic review and meta-analysis. Biol Blood Marrow Transpl 22:651\u2013657. https:\/\/doi.org\/10.1016\/j.bbmt.2015.10.019","journal-title":"Biol Blood Marrow Transpl"},{"key":"6389_CR4","doi-asserted-by":"publisher","first-page":"E52","DOI":"10.1002\/ajh.24981","volume":"93","author":"S Godet","year":"2018","unstructured":"Godet S, Protin C, Dupuis J et al (2018) Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO). Am J Hematol 93:E52\u2013E54. https:\/\/doi.org\/10.1002\/ajh.24981","journal-title":"Am J Hematol"},{"key":"6389_CR5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bjh.12425","volume":"162","author":"A Shah","year":"2013","unstructured":"Shah A, Andersson TM-L, Rachet B et al (2013) Survival and cure of acute myeloid leukaemia in England, 1971\u20132006: A population-based study. Br J Haematol 162:509\u2013516. https:\/\/doi.org\/10.1111\/bjh.12425","journal-title":"Br J Haematol"},{"key":"6389_CR6","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","volume":"33","author":"BA Jonas","year":"2019","unstructured":"Jonas BA, Pollyea DA (2019) How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia 33:2795\u20132804. https:\/\/doi.org\/10.1038\/s41375-019-0612-8","journal-title":"Leukemia"},{"key":"6389_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"6389_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ajh.25000","volume":"93","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Rausch CR, Benton C et al (2018) Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 93:401\u2013407. https:\/\/doi.org\/10.1002\/ajh.25000","journal-title":"Am J Hematol"},{"key":"6389_CR9","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.ctrv.2013.03.006","volume":"39","author":"P Robak","year":"2013","unstructured":"Robak P, Robak T (2013) Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treat Rev 39:851\u2013861. https:\/\/doi.org\/10.1016\/j.ctrv.2013.03.006","journal-title":"Cancer Treat Rev"},{"key":"6389_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/1042819021000054670","volume":"44","author":"KU Chow","year":"2003","unstructured":"Chow KU, Boehrer S, Napieralski S et al (2003) In AML cell lines ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential. Leuk Lymphoma 44:165\u2013173. https:\/\/doi.org\/10.1080\/1042819021000054670","journal-title":"Leuk Lymphoma"},{"key":"6389_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1182\/blood.V87.1.256.256","volume":"87","author":"V Gandhi","year":"1996","unstructured":"Gandhi V, Estey E, Keating MJ et al (1996) Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 87:256\u2013264","journal-title":"Blood"},{"key":"6389_CR12","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","volume":"13","author":"S Pei","year":"2023","unstructured":"Pei S, Shelton IT, Gillen AE et al (2023) A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov 13:2032\u20132049. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1297","journal-title":"Cancer Discov"},{"key":"6389_CR13","doi-asserted-by":"publisher","unstructured":"Steinauer N, McCullough K, Al-Kali A et al (2024) Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent. https:\/\/doi.org\/10.3324\/haematol.2024.284962. Haematologica","DOI":"10.3324\/haematol.2024.284962"},{"key":"6389_CR14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/leu.2012.303","volume":"27","author":"F Ferrara","year":"2013","unstructured":"Ferrara F, Barosi G, Venditti A et al (2013) Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: A project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia 27:997\u2013999. https:\/\/doi.org\/10.1038\/leu.2012.303","journal-title":"Leukemia"},{"key":"6389_CR15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"6389_CR16","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ et al (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642\u20134649. https:\/\/doi.org\/10.1200\/JCO.2003.04.036","journal-title":"J Clin Oncol"},{"key":"6389_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41408-024-00982-3","volume":"14","author":"Y-Y Li","year":"2024","unstructured":"Li Y-Y, Ge S-S, Huang Y-H et al (2024) Efficacy and safety of Cladribine, low-dose cytarabine and venetoclax in relapsed\/refractory acute myeloid leukemia: results of a pilot study. Blood Cancer J 14:12. https:\/\/doi.org\/10.1038\/s41408-024-00982-3","journal-title":"Blood Cancer J"},{"key":"6389_CR18","doi-asserted-by":"publisher","unstructured":"Garciaz S, Hospital M-A, Alary A-S et al (2022) Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients. Cancers (Basel) 142025. https:\/\/doi.org\/10.3390\/cancers14082025","DOI":"10.3390\/cancers14082025"},{"key":"6389_CR19","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1002\/cncr.35388","volume":"130","author":"J Senapati","year":"2024","unstructured":"Senapati J, Kantarjian HM, Bazinet A et al (2024) Lower intensity therapy with cladribine\/low dose Cytarabine\/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer 130:3333\u20133343. https:\/\/doi.org\/10.1002\/cncr.35388","journal-title":"Cancer"},{"key":"6389_CR20","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/JCO.21.02823","volume":"40","author":"TM Kadia","year":"2022","unstructured":"Kadia TM, Reville PK, Wang X et al (2022) Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 40:3848\u20133857. https:\/\/doi.org\/10.1200\/JCO.21.02823","journal-title":"J Clin Oncol"},{"key":"6389_CR21","doi-asserted-by":"publisher","unstructured":"Senapati J, Loghavi S, Reville PK et al (2023) Outcomes of patients with newly diagnosed acute myeloid leukemia and TP53 mutation\/loss treated on the phase 2 study of venetoclax added to alternating cladribine plus low-dose cytarabine and Azacitidine: A subgroup analysis. Blood 142. https:\/\/doi.org\/10.1182\/blood-2023-179380","DOI":"10.1182\/blood-2023-179380"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06389-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06389-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06389-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T06:37:27Z","timestamp":1749105447000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06389-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6389"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06389-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved, and the written informed consent was waived by the ethics committee of the first affiliated hospital of University of Science and Technology of China (2024-RE-449) due to the retrospective nature of the review, and confirmed that the data was anonymized and maintained with confidentiality. The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}